At the Vitrolife Group, we work every day to unlock the full potential of science and technology to reduce the barriers towards building a family. Together we help our customers and their patients to fulfill the dream of having a baby.
The Marketing Manager IVF Genetic Testing leads strategic marketing initiatives across PGT A, PGT M, PGT SR, EMMA ALICE, ERA, and emerging genomic technologies supporting reproductive medicine. This role is responsible for building market awareness, driving demand, and enabling commercial success in a highly technical and clinically sensitive environment.
The ideal candidate combines knowledge of IVF workflows and genetic testing with strong capabilities in messaging, content development, product launches, and customer insights. This role serves as a key bridge between commercial teams, clinical scientists, and genetic counselors to ensure accurate and compelling communication with clinicians, embryologists, and patients.
An offer of employment is contingent on the successful passing of a background check. In compliance with federal law, all persons hired will be required to verify identity and eligibility to work in the United States and to complete the required employment eligibility verification form upon hire.
Vitrolife Group is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. We support our customers by improving their clinical practice for the patient's outcome of fertility treatment.
We are currently approximately 1 100 colleagues worldwide, with headquarters in Gothenburg, Sweden. Vitrolife Group's products and services are available in more than 110 countries through our own presence in 30 countries and a network of distributors. Vitrolife Group is a sustainable market leader and aims to be the preferred partner for IVF-clinics by providing superior products and services with the vision of fulfilling the dream of having a baby. The Vitrolife share is listed on Nasdaq Stockholm.

The Vitrolife Group is a world-leading global provider of medical devices and genetic testing testing solutions. Dedicated to the reproductive-health market since 1994, we have grown by focusing on product development, groundbreaking research, consistent quality control and acquisitions of innovative companies in the industry.
In 2021, Vitrolife acquired Igenomix, a leader in reproductive genetic testing services primarily for IVF clinics. Together we are now the Vitrolife Group, a global leader in reproductive health focused on supporting our customers and patients worldwide to improve treatment outcomes – always with sustainability in mind. Based on science and advanced research capabilities, our aim is to deliver products and services for the entire reproductive-health journey, providing consistent performance and guaranteed quality.
Currently, we are approximately 1,100 people worldwide headquartered in Gothenburg, Sweden. Our products and services are available in more than 125 countries, through our own presence in more than 25 countries and a vast network of distributors for the rest of the world. We are on a mission to be the leading valued solution provider in reproductive health and to support customers with successful treatment outcomes.